Pharmaceutical Research and Manufacturers of America, the National Association of Community Health Centers, and the National Hispanic Medical Association this morning jointly issued a 10-point plan and created a nonprofit group to ensure that the 340B program “benefits patients and
…
The U.S. House Committee on Oversight and Accountability last week launched an investigation into how “anticompetitive tactics” by the three largest pharmacy benefit managers—Express Scripts, CVS Caremark, and OptumRx—are driving up healthcare costs and hurting patient care within federal health
…
Generic and specialty drug manufacturer Amneal Pharmaceuticals is offering refunds for 340B overcharges on an 18-page-long list of products for purchases between Q3 2019 and Q3 2022.
The U.S. Health Resources and Services Administration posted New Jersey-based Amneal’s notice to
…
The National Association of Community Health Centers says in a new advocacy document “it’s time to reform the 340B program to recognize the complexities of today’s healthcare system and ensure that true safety-net providers continue to have access to critical
…
Drug manufacturer Lilly’s announcement last week that it is slashing the price of Humalog, its most commonly prescribed insulin, may have been less about altruism and more about avoiding exposure to bigger Medicaid rebates, a prominent drug pricing expert says.
…
Generic drug manufacturer Zydus Pharmaceuticals USA said in a recent public notice it will pay refunds for 340B overcharges that occurred mostly in the first two quarters of 2022. The products include Zydus’ equivalents of the widely prescribed antibiotic Zithromax,
…
The 340B program—and whether it needs change, protection, or both—came up often today during a U.S. Senate hearing on federal funding of community health centers.
The bulk of health centers’ federal grant funding—about $5.8 billion annually from the U.S. Health
…
Associations representing community health centers and brand drug manufacturers are jointly developing 340B policy proposals for Congress to consider, hospital group 340B Health told its members yesterday.
The National Association of Community Health Centers said yesterday that it had no
…
UPDATED Thursday March 2, 2023, 12:30 p.m. EDT to include comment from HRSA.
The U.S. Health Resources and Services Administration has asked multiple hospitals to explain how they determine patient eligibility for 340B drugs, how they define, track, and use
…
The federal government may ask all 14 judges on the U.S. Third Circuit Court of Appeals to review a three-judge panel’s unanimous January opinion upholding AstraZeneca, Novo Nordisk, and Sanofi’s restrictions on 340B pricing when their drugs are shipped to
…
×
*Sign up for news summaries and alerts from 340B Report